The Efficacy and Safety of Adding on or Switching to Peginterferon Α‐2b in HBeAg‐positive Chronic Hepatitis B Patients with Long‐term Entecavir Treatment: a Multicentre Randomised Controlled Trial
Qiankun Hu,Xun Qi,Yiqi Yu,Yueqiu Gao,Xinxin Zhang,Qianqian Wang,Xueyun Zhang,Yunhui Zhuo,Jing Li,Jiming Zhang,Liang Chen,Yuxian Huang
DOI: https://doi.org/10.1111/apt.17222
IF: 9.524
2022-01-01
Alimentary Pharmacology & Therapeutics
Abstract:Background & Aims The strategies of adding on or switching to peginterferon (PEG-IFN) therapy improved the serological response rates in nucleos(t)ide analogues experienced chronic hepatitis B (CHB) patients. However, robust data on which combination strategy is more effective remain lacking. Methods In this multicentre, parallel, open-label, randomised, controlled trial, HBeAg-positive CHB patients with entecavir (ETV) treatment >= 2 years, hepatitis B surface antigen (HBsAg) <3000 IU/ml, HBeAg <200S/CO and HBV DNA <50 IU/ml were randomly assigned in a 1:1:1 ratio to add on PEG-IFN (add-on), switch to PEG-IFN (switch-to) or continue ETV monotherapy for 48 weeks. The primary endpoint was HBeAg seroconversion at week 48. Results A total of 153 patients were randomised into three treatment arms (50 in add-on, 52 in switch-to and 51 in monotherapy). Compared with continuous ETV monotherapy, both add-on and switch-to strategies achieved higher rates of HBeAg seroconversion (18.0% vs. 2.0%, p = 0.007; 19.2% vs. 2.0%, p = 0.005, respectively), HBeAg loss (24.0% vs. 5.9%, p = 0.010; 23.1% vs. 5.9%, p = 0.013, respectively), HBsAg < 100 IU/ml (30.0% vs. 0%, p < 0.001; 34.6% vs. 0%, p < 0.001, respectively), and higher HBsAg reduction (-0.90 vs. -0.06 log(10)IU/ml, p < 0.001; -0.92 vs. -0.06 log(10)IU/ml, p < 0.001, respectively) at week 48. The efficacy was comparable between add-on and switch-to arms (p > 0.05). Adverse events were mainly related to PEG-IFN but generally tolerable. Conclusion In CHB patients who achieved virological response with long-term ETV treatment, both adding on and switching to PEG-IFN therapy are alternative strategies to result in higher rates of HBeAg seroconversion and higher HBsAg reduction compared with continuous ETV monotherapy. Clinical trials registration Chinese Clinical Trial Registry (, identifier: ChiCTR-IPR-17012055).